O'Day Kathleen, Gorlick Richard
Department of Pediatrics, Division of Pediatric Hematology/Oncology, The Children's Hospital at Montefiore, 3415 Bainbridge Avenue, Rosenthal 3rd floor, Bronx, NY 10467, USA.
Expert Rev Anticancer Ther. 2009 Apr;9(4):511-23. doi: 10.1586/era.09.7.
Osteosarcoma is the most common malignant primary bone tumor in childhood. Despite multiagent chemotherapy and aggressive surgical resection, 30% of patients with localized disease and 80% of patients with metastatic disease at diagnosis will relapse. Survival for these patients has remained unchanged over the past 20 years. A number of novel agents in various stages of development hold promise for improving therapy for patients with osteosarcoma. This article will focus on novel therapeutic approaches, including agents targeting signal-transduction pathways, inhibitors of the tumor microenvironment and immunomodulatory agents, as well as overcoming resistance mechanisms and the use of novel delivery mechanisms.
骨肉瘤是儿童期最常见的原发性恶性骨肿瘤。尽管采用了多药化疗和积极的手术切除，但诊断时患有局限性疾病的患者中有30%以及患有转移性疾病的患者中有80%会复发。在过去20年中，这些患者的生存率一直没有变化。一些处于不同开发阶段的新型药物有望改善骨肉瘤患者的治疗。本文将重点关注新型治疗方法，包括靶向信号转导通路的药物、肿瘤微环境抑制剂和免疫调节剂，以及克服耐药机制和新型给药机制的应用。
